Combined analysis of circulating tumor cells and PSMA imaging metrics to predict efficacy of 177Lu-PSMA-617 in metastatic prostate cancer. Lewis Y antigen as a novel target for CAR (chimeric antigen ...

Radiographic progression free survival (RECIST 1.1 and PCWG3) CTCAE v5.0 ...

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor ...

HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...

Enzalutamide may offer a survival advantage compared with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC), according to 2 US studies of older men. Overall survival ...

Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...